Login to Your Account

Other News To Note

Monday, June 25, 2012
• OxiGene Inc., of South San Francisco, said it signed an exclusive, worldwide licensing deal with Angiogene Pharmaceuticals Ltd., of Oxford, UK, for data, development plans, know-how, patents and other intellectual property rights relative to its vascular-disrupting agent program for neuroendocrine cancers, focused specifically on carcinoid syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription